Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21589071 | 1.00 | CACNA2D1 (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27857355 | 1.00 | CACNA2D1 (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Acetic Acid SCHEMBL28029629 | 0.95 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL234997 | 0.91 | MGAM (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL28011595 | 0.86 | CACNA2D1 (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL15969817 | 0.84 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3291702 | 0.84 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL15698640 | 0.84 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL7980052 | 0.84 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3291696 | 0.84 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102465157-A | Preparation of pregabalin chiral intermediate by biological enzyme method | ZHEJIANG JIUZHOU PHARM CO LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2071032-A2 | The use of enzymatic resolution for the preparation of intermediates of pregabalin | Teva Pharmaceutical Industries Ltd (IL) | 2009-06-17 | — | — | EP | disclosed |
| EP-2071032-A2 | The use of enzymatic resolution for the preparation of intermediates of pregabalin | Teva Pharmaceutical Industries Ltd (IL) | 2009-06-17 | — | — | EP | disclosed |
| CN-101454459-A | The use of enzymatic resolution for the preparation of intermediates of pregabalin | TEVA PHARMA (IL) | 2009-06-10 | — | — | CN | disclosed |
| EP-1913147-A2 | THE USE OF ENZYMATIC RESOLUTION FOR THE PREPARATION OF INTERMEDIATES OF PREGABALIN | Teva Pharmaceutical Industries Ltd (IL) | 2008-04-23 | — | — | EP | disclosed |
| US-20080026433-A1 | Use of enzymatic resolution for the preparation of intermediates of pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | US | disclosed |
| US-20080026433-A1 | Use of enzymatic resolution for the preparation of intermediates of pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | US | disclosed |
| WO-2007143113-A2 | THE USE OF ENZYMATIC RESOLUTION FOR THE PREPARATION OF INTERMEDIATES OF PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007143113-A2 | THE USE OF ENZYMATIC RESOLUTION FOR THE PREPARATION OF INTERMEDIATES OF PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |